fludarabine
fludarabine: 197 clinical trials tracked.
fludarabine evidence translation
What we can confirm
197 tracked trials
What it means
What to watch
Prepared research question
What is verified about fludarabine, and what remains unknown?
Traceable citations · Unknowns marked
See linked entities and source evidence8 indications · 32 study sponsors
Related indications
Clinical Trials (197)showing 10 most recent
Testing a Reduced Conditioning Regimen FB2A2 Preceded by a Fractionated Radio-immunotherapy (RIT) With 90Y-Epratuzumab Before Allogeneic Stem Cell Transplantation for Patients With Lymphocyte B CD22 Positive Acute Lymphoblastic Leukemia
Primary endpoint: Determination of the maximum tolerated dose (MTD)
A Phase 1 Study to Evaluate BAFFR-Targeting CAR T Cells for Patients With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia
Primary endpoint: Incidence of adverse events
A Phase I Trial of Lymphodepletion Intensification With Low Dose Total Body Irradiation With Dose Expansion for Standard-of-Care Tisagenlecleucel in Patients With Large B-Cell Lymphoma
Primary endpoint: Dose-limiting toxicities
A Multicenter, Phase 1, Safety and Tolerability Study of CC-97540 (BMS- 986353) in Anti-Aquaporin 4 Antibody Positive Neuromyelitis Optica Patients
Primary endpoint: To evaluate the safety and tolerability of CC-97540 (BMS-986353) in participants with anti-AQP4 antibody positive NMO as determined by the proportion of patients experiencing DLTs
A Phase 1/2 Trial of ADI-212 (Engineered γδ Chimeric Antigen Receptor [CAR] Vδ1 T Cells Targeting PSMA) in Adults With Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Primary endpoint: The incidence of Subjects with Dose Limiting Toxicity within each dose level
A Phase 2, Multicenter, Open-Label Study of Zolacabtagene Autoleucel (BMS-986353), CD19-Targeted NEX-T CAR T Cells, in Participants With Chronic Immune Thrombocytopenia (cITP) and Autoimmune Hemolytic Anemia (AIHA)
Primary endpoint: Cohort 1 Part A: Number of participants with treatment-emergent adverse events (TEAEs)
A Phase 3, Randomized, Open-label, Multicenter Study to Compare the Efficacy and Safety of BMS-986353, CD19-targeted NEX-T CAR T Cells, Versus Standard of Care in Participants With Active Systemic Sclerosis (Breakfree-SSc)
Primary endpoint: The absolute change from baseline in Forced Vital Capacity (FVC) in mL
A Phase III, Open-label, Multicentre, Randomised Study Comparing Consolidation Treatment With AZD0120, an Autologous Dual Targeting Chimeric Antigen Receptor T-cell (CAR-T) Therapy Directed Against BCMA and CD19, Versus Autologous Stem Cell Transplant (ASCT) in Participants With Newly Diagnosed Multiple Myeloma Who Are Transplant Eligible (TE NDMM) (DURGA-6)
Primary endpoint: Progression-Free Survival (PFS)
CD45RA-depleted CD19-CAR T Cell Consolidation After TCRαβ+/CD19 B Cell-depleted Haploidentical Hematopoietic Cell Transplantation for Relapsed/Refractory CD19+ ALL and Lymphoma
Primary endpoint: To assess the safety of combining CD19-CAR(Mem) T cells after TCRαβ+/CD19 depleted haploidentical donor transplantation for pediatric patients with relapsed/refractory CD19+ B-cell malignancies.
Dual Administration Of Intraperitoneal And Intravenous TROP2-Directed CAR-NK With TGF-Beta Receptor 2 (TGFBR2) Knock Out (KO) Therapy For Colorectal Cancer-Related Peritoneal Carcinomatosis: A Phase 1/2 Trial ("Chip-CRC Trial")
Primary endpoint: Safety and adverse events (AEs